Below is the un-edited press release from PR Newswire and United Business Media. It describes a recent project Omnica Corporation (www.omnica.com) contributed to for Volcano Therapeutics. Our role was to perform all research, development, engineering, prototyping, design control and documentation. We also constructed 10 working devices used for clinical studies. Development of the catheter was performed elsewhere.
Volcano Therapeutics announces the issuance of a patent for intravascular thermography used in the detection of vulnerable plaque.
Volcano Therapeutics Inc
(IMMEDIAPRESS) Brussels, Belgium, November – Volcano Therapeutics, Inc., an early stage medical device company, announced today that the U.S. patent office has issued a new patent covering methods of identifying vulnerable plaque through the use of intravascular thermography. Volcano Therapeutics is focused on the discovery, development and commercialisation of products for the detection and treatment of vulnerable plaques located in the coronary or peripheral arteries.
The patent (6,475,159) broadly covers methods for the use of intravascular thermography to detect vulnerable plaque lesions. The issued claims include:
— A method of identifying a vulnerable atherosclerotic plaque in a living vessel comprising the steps of: detecting a region along the luminal wall having a temperature that is higher than that of an adjacent region; and locating the vulnerable plaque based upon the higher temperature of the detected region.
— The method of the previous claim wherein said detecting comprises measuring the temperature of a plurality of sites along the lumen wall of said vessel, determining average vessel wall temperature and determining a temperature elevation in at least one said site of up to 5 degrees C above said vessel wall temperature.
— The method of the 1st claim wherein said detecting comprises employing an intravenous or non-invasive thermography device.
— A method of identifying a vulnerable atherosclerotic plaque in a living endarterectomy specimen comprising the steps of: detecting a region of said specimen having a temperature that is higher than that of an adjacent region; and locating the vulnerable plaque based upon the higher temperature of the detected region.
Scott Huennekens, President & CEO of Volcano Therapeutics, noted that the issuance of this patent expands further the patent protection for intravascular thermography and represents a significant milestone to strengthening the company's intellectual property portfolio — which now includes 12 issued patents and over 20 patents pending. Mr. Huennekens commented, ''this patent builds on our extremely strong patent position in intravascular thermography. We fully intend to enforce our patent rights in the US and abroad in the months and years ahead.''
Volcano Therapeutics, Inc., a privately held early stage medical device company with the European office based in Brussels, Belgium and the headquarters in Laguna Hills, CA. The company was founded in 2001 and partnered with MedPole earlier this year for all European business initiatives. Volcano is focused on the discovery, development and commercialisation of products for the detection and treatment of vulnerable plaque in the coronary arteries and peripheral vascular system. Currently under development are technologies that could be potentially useful in detecting and treating patients who are at risk for developing plaque rupture and subsequent adverse cardiac events. For more information, please visit us at http://www.volcanotherapeutics.com .
Per maggiori informazioni: Contact: EU, Michel Lussier President & CEO of MedPole, +32 2 6 19 20; or US, Vince Burgess, Vice President of Marketing of Volcano Therapeutics, Inc., +1-949-582-3435